Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®

NCT01908192 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: NaBen®
DRUG: Placebo

Sponsor

SyneuRx International (Taiwan) Corp